Melexis: update on the share buy-back program

Press release - Regulated Information

Melexis: update on the share buy-back program

Ieper, Belgium – 24 August 2026, 17.45 hrs CET

Melexis reports the purchase of 3,919 Melexis shares on Euronext Brussels in the period from 17 August 2026 to 21 August 2026, related to the share buy-back program announced on 10 December 2025.

Under the current share buy-back program for up to 850,000 shares, Melexis purchased 219,219 treasury shares.

Including 831,491 shares purchased under a previous share buy-back program, Melexis now holds 1,050,710 treasury shares.

Contact
Investor Relations
Email: [email protected]

About Melexis
Melexis designs, develops, and delivers edge sensor and driver solutions with a heart for people and planet. Its mission is to empower engineers to turn their ideas into applications that support the best imaginable future, one that is safe, comfortable and sustainable. Melexis specializes in powertrain, thermal management, lighting, e-brake, e-steering and battery solutions for the automotive sector. It also expands its presence in the emerging markets of sustainable world, alternative mobility, robotics, and digital health.
Founded in 1989 in Belgium, Melexis has grown to employ approximately 2,000 people in 12 countries, delivering cutting-edge technology to customers worldwide.

For more information, visit www.melexis.com or follow Melexis on LinkedIn, and YouTube.

Disclaimer
Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forward-looking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.

You May Also Be Interested In

• Federal Filings Joins Client Vogenx at the Nasdaq Opening Bell
• FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
• Natural Grocers® Hosts Virtual Hiring Event for Los Alamos, New Mexico Location on August 27, 2026